English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

To assess the association of the programmed cell death ligand 1 (PD‐L1) with cisplatin‐based neo‐adjuvant chemotherapy (NAC) response, we investigated the level of PD‐L1 and found increased PD‐L1 expression in chemo‐resistant tumors compared with chemo‐sensitive tumors according to RNA‐Seq analysis. In a cohort of 92 patients with  NAC , the positive staining of  PD ‐ L 1 was correlated with  TNM  stage, lower sensitive‐response rates and shorter overall survival rates. In another 30 paired tumor specimens pre‐ and post‐chemotherapy, the patients with high  PD ‐ L 1 expression post‐chemotherapy had a worse outcome and higher stable disease rate.  CD 8 +  tumor‐infiltrating lymphocytes were found to be related to chemosensitive response and better prognosis and negative  PD ‐ L 1 expression. Furthermore, in two patient‐derived xenograft models and cell lines  A 549 and  PC ‐9, cisplatin upregulated  PD ‐ L 1 expression, and the enhancement of  PD ‐ L 1 in cancer cell lines was in a drug dose‐dependent manner. Moreover, the depletion of  PD ‐ L 1 significantly reduced cisplatin resistance. When phosphatidylinositol 3‐kinase/protein kinase B signaling was inhibited by corresponding inhibitors,  PD ‐ L 1 expression was downregulated and apoptosis was upregulated in the cisplatin‐treated cancer cells. These results suggest that the upregulation of  PD ‐ L 1 promotes a resistance response in lung cancer cells that might be through activation of the phosphatidylinositol 3‐kinase/protein kinase  B  pathway and suppression of tumor‐infiltrating lymphocytes. The high expression of  PD ‐ L 1 after  NAC  could be an indication of therapeutic resistance and poor prognosis in patients with non‐small‐cell lung cancer.

cancer science

Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy